Keywords: Gilead Sciences, Calistoga Pharma, M&A, Cancer, Inflammatory diseases
Gilead to acquire Calistoga in $375 million, plus milestones, deal
Article | 23 February 2011
USA-based Gilead Sciences (Nasdaq: GILD) has signed a definitive agreement to purchase Calistoga Pharmaceuticals, a privately-held biotechnology company focused on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
